Instituto Alexander Fleming ( Site 0306)

Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ

2 studies enrolling now · 2 studies all time

What they study most

Carcinoma in Situ, Non-Muscle Invasive Bladder Neoplasms, Non-small Cell Lung Cancer (NSCLC), Urinary Bladder Neoplasms

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) — Recruiting now
• A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) — Recruiting now